What CHAMPION-AF means for the future of left atrial appendage closure

In this discussion, Philippe Garot and Saibal Kar review the implications of the CHAMPION-AF trial for the future of left atrial appendage closure (LAAC). The study demonstrated that LAAC is non-inferior to NOACs for preventing stroke, systemic embolism and death, while significantly reducing long-term bleeding.

These findings suggest a potential shift from LAAC as a therapy reserved for patients unable to take anticoagulation toward a broader, patient-centred strategy, where device-based and pharmacological options can be considered equally. Looking ahead, ongoing innovation and combined procedural approaches may further expand the role of LAAC in stroke prevention.